Skip to main content
PMC home page
British Medical Journal logoLink to British Medical Journal
. 1980 Jan 12;280(6207):66–68. doi: 10.1136/bmj.280.6207.66

Molecular pathology of schizophrenia: more than one disease process?

T J Crow
PMCID: PMC1600263  PMID: 6101544

Full text

PDF
66

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andén N. E. Dopamine turnover in the corpus striatum and the lumbic system after treatment with neuroleptic and anti-acetylcholine drugs. J Pharm Pharmacol. 1972 Nov;24(11):905–906. doi: 10.1111/j.2042-7158.1972.tb08912.x. [DOI] [PubMed] [Google Scholar]
  2. Bowers M. B., Jr Central dopamine turnover in schizophrenic syndromes. Arch Gen Psychiatry. 1974 Jul;31(1):50–54. doi: 10.1001/archpsyc.1974.01760130034005. [DOI] [PubMed] [Google Scholar]
  3. CARLSSON A., LINDQVIST M. EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN. Acta Pharmacol Toxicol (Copenh) 1963;20:140–144. doi: 10.1111/j.1600-0773.1963.tb01730.x. [DOI] [PubMed] [Google Scholar]
  4. Cotes P. M., Crow T. J., Johnstone E. C., Bartlett W., Bourne R. C. Neuroendocrine changes in acute schizophrenia as a function of clinical state and neuroleptic medication. Psychol Med. 1978 Nov;8(4):657–665. doi: 10.1017/s0033291700018869. [DOI] [PubMed] [Google Scholar]
  5. Creese I., Burt D. R., Snyder S. H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 1976 Apr 30;192(4238):481–483. doi: 10.1126/science.3854. [DOI] [PubMed] [Google Scholar]
  6. Cross A. J., Crow T. J., Killpack W. S., Longden A., Owen F., Riley G. J. The activities of brain dopamine-beta-hydroxylase and catechol-O-methyl transferase in schizophrenics and controls. Psychopharmacology (Berl) 1978 Oct 31;59(2):117–121. doi: 10.1007/BF00427744. [DOI] [PubMed] [Google Scholar]
  7. Crow T. J., Baker H. F., Cross A. J., Joseph M. H., Lofthouse R., Longden A., Owen F., Riley G. J., Glover V., Killpack W. S. Monoamine mechanisms in chronic schizophrenia: post-mortem neurochemical findings. Br J Psychiatry. 1979 Mar;134:249–256. doi: 10.1192/bjp.134.3.249. [DOI] [PubMed] [Google Scholar]
  8. Crow T. J., Deakin J. F., Longden A. The nucleus accumbens--possible site of antipsychotic action of neuroleptic drugs? Psychol Med. 1977 May;7(2):213–221. doi: 10.1017/s0033291700029287. [DOI] [PubMed] [Google Scholar]
  9. Crow T. J., Ferrier I. N., Johnstone E. C., Macmillan J. F., Owens D. G., Parry R. P., Tyrrell D. A. Characteristics of patients with schizophrenia or neurological disorder and virus-like agent in cerebrospinal fluid. Lancet. 1979 Apr 21;1(8121):842–844. doi: 10.1016/s0140-6736(79)91262-5. [DOI] [PubMed] [Google Scholar]
  10. Crow T. J., Gillbe C. Brain dopamine and behaviour. A critical analysis of the relationship between dopamine antagonism and therapeutic efficacy of neuroleptic drugs. J Psychiatr Res. 1974;11:163–172. doi: 10.1016/0022-3956(74)90088-0. [DOI] [PubMed] [Google Scholar]
  11. Crow T. J., Johnstone E. C., Deakin J. F., Longden A. Dopamine and schizophrenia. Lancet. 1976 Sep 11;2(7985):563–566. doi: 10.1016/s0140-6736(76)91807-9. [DOI] [PubMed] [Google Scholar]
  12. Crow T. J., Mitchell W. S. Subjective age in chronic schizophrenia: evidence for a sub-group of patients with defective learning capacity? Br J Psychiatry. 1975 Apr;126:360–363. doi: 10.1192/bjp.126.4.360. [DOI] [PubMed] [Google Scholar]
  13. Crow T. J., Stevens M. Age disorientation in chronic schizophrenia: the nature of the cognitive deficit. Br J Psychiatry. 1978 Aug;133:137–142. doi: 10.1192/bjp.133.2.137. [DOI] [PubMed] [Google Scholar]
  14. Crow T. J. Viral causes of psychiatric disease. Postgrad Med J. 1978 Nov;54(637):763–767. doi: 10.1136/pgmj.54.637.763. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. HAUG J. O. Pneumoencephalographic studies in mental disease. Acta Psychiatr Scand Suppl. 1962;38(165):1–104. [PubMed] [Google Scholar]
  16. Johnstone E. C., Crow T. J., Frith C. D., Carney M. W., Price J. S. Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet. 1978 Apr 22;1(8069):848–851. doi: 10.1016/s0140-6736(78)90193-9. [DOI] [PubMed] [Google Scholar]
  17. Johnstone E. C., Crow T. J., Frith C. D., Stevens M., Kreel L., Husband J. The dementia of dementia praecox. Acta Psychiatr Scand. 1978 Apr;57(4):305–324. doi: 10.1111/j.1600-0447.1978.tb06899.x. [DOI] [PubMed] [Google Scholar]
  18. Jospeh M. H., Baker H. F., Crow T. J., Riley G. J., Risby D. Brain tryptophan metabolism in schizophrenia: a post mortem study of metabolites of the serotonin and kynurenine pathways in schizophrenic and control subjects. Psychopharmacology (Berl) 1979 Apr 25;62(3):279–285. doi: 10.1007/BF00431959. [DOI] [PubMed] [Google Scholar]
  19. Kornetsky C. Hyporesponsivity of chronic schizophrenic patients to dextroamphetamine. Arch Gen Psychiatry. 1976 Dec;33(12):1425–1428. doi: 10.1001/archpsyc.1976.01770120029002. [DOI] [PubMed] [Google Scholar]
  20. Lee T., Seeman P., Tourtellotte W. W., Farley I. J., Hornykeiwicz O. Binding of 3H-neuroleptics and 3H-apomorphine in schizophrenic brains. Nature. 1978 Aug 31;274(5674):897–900. doi: 10.1038/274897a0. [DOI] [PubMed] [Google Scholar]
  21. Letemendia F. J., Harris A. D. Chlorpromazine and the untreated chronic schizophrenic: a long-term trial. Br J Psychiatry. 1967 Sep;113(502):950–958. doi: 10.1192/bjp.113.502.950. [DOI] [PubMed] [Google Scholar]
  22. Miller R. J., Hiley C. R. Anti-muscarinic properties of neuroleptics and drug-induced Parkinsonism. Nature. 1974 Apr 12;248(449):596–597. doi: 10.1038/248596a0. [DOI] [PubMed] [Google Scholar]
  23. Muller P., Seeman P. Brain neurotransmitter receptors after long-term haloperidol: dopamine, acetylcholine, serotonin, alpha-noradrenergic and naloxone receptors. Life Sci. 1977 Dec 15;21(12):1751–1758. doi: 10.1016/0024-3205(77)90155-2. [DOI] [PubMed] [Google Scholar]
  24. Murphy D. L., Wyatt R. J. Reduced monoamine oxidase activity in blood platelets from schizophrenic patients. Nature. 1972 Jul 28;238(5361):225–226. doi: 10.1038/238225a0. [DOI] [PubMed] [Google Scholar]
  25. Owen F., Cross A. J., Crow T. J., Longden A., Poulter M., Riley G. J. Increased dopamine-receptor sensitivity in schizophrenia. Lancet. 1978 Jul 29;2(8083):223–226. doi: 10.1016/s0140-6736(78)91740-3. [DOI] [PubMed] [Google Scholar]
  26. Post R. M., Fink E., Carpenter W. T., Jr, Goodwin F. K. Cerebrospinal fluid amine metabolites in acute schizophrenia. Arch Gen Psychiatry. 1975 Aug;32(8):1063–1069. doi: 10.1001/archpsyc.1975.01760260127011. [DOI] [PubMed] [Google Scholar]
  27. Randrup A., Munkvad I. Special antagonism of amphetamine-induced abnormal behaviour. Inhibition of stereotyped activity with increase of some normal activities. Psychopharmacologia. 1965 May 21;7(6):416–422. doi: 10.1007/BF00402364. [DOI] [PubMed] [Google Scholar]
  28. Randrup A., Munkvad I. Stereotyped activities produced by amphetamine in several animal species and man. Psychopharmacologia. 1967;11(4):300–310. doi: 10.1007/BF00404607. [DOI] [PubMed] [Google Scholar]
  29. Seeman P., Lee T., Chau-Wong M., Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 1976 Jun 24;261(5562):717–719. doi: 10.1038/261717a0. [DOI] [PubMed] [Google Scholar]
  30. Stein L., Wise C. D. Possible etiology of schizophrenia: progressive damage to the noradrenergic reward system by 6-hydroxydopamine. Science. 1971 Mar 12;171(3975):1032–1036. doi: 10.1126/science.171.3975.1032. [DOI] [PubMed] [Google Scholar]
  31. Tyrrell D. A., Parry R. P., Crow T. J., Johnstone E., Ferrier I. N. Possible virus in schizophrenia and some neurological disorders. Lancet. 1979 Apr 21;1(8121):839–841. doi: 10.1016/s0140-6736(79)91261-3. [DOI] [PubMed] [Google Scholar]
  32. Weinberger D. R., Torrey E. F., Neophytides A. N., Wyatt R. J. Lateral cerebral ventricular enlargement in chronic schizophrenia. Arch Gen Psychiatry. 1979 Jul;36(7):735–739. doi: 10.1001/archpsyc.1979.01780070013001. [DOI] [PubMed] [Google Scholar]
  33. Woolley D. W., Shaw E. A BIOCHEMICAL AND PHARMACOLOGICAL SUGGESTION ABOUT CERTAIN MENTAL DISORDERS. Proc Natl Acad Sci U S A. 1954 Apr;40(4):228–231. doi: 10.1073/pnas.40.4.228. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES